Femasys Inc
femasys.comFemasys Inc. (NASDAQ: FEMY) is a medical device company focused on non-surgical women's reproductive health products. Revenue comes from product sales of its commercial-stage devices, which totaled $2,293,313 in FY2025, up 40.8% from $1,629,108 in FY2024 (per the 10-K filed 2026-03-31). The company remains pre-profitability, posting a net loss of $18,627,887 in FY2025, funded in part through convertible notes and equity financings. Its lead pipeline product, FemBloc, is a non-surgical permanent contraception system for fallopian tube occlusion that received CE mark certification under EU MDR as of early 2025, representing the first regulatory approval for the FemBloc delivery system globally. The companion product FemChec is used as a confirmation test following FemBloc placement. Femasys sells into the women's healthcare channel, targeting hospitals and healthcare practitioners, and operates under a direct transactional product-sales model.
Products & Services
FemBloc: non-surgical permanent contraception device for fallopian tube occlusion, delivered transcervically. FemChec: confirmation test used to verify bilateral occlusion three months post-FemBloc procedure. FemBloc received CE mark certification under EU MDR in March 2025.
Revenue Model
Transactional product sales of medical devices. FY2025 sales were $2,293,313 against cost of sales of $872,400, yielding gross profit before depreciation. The company carries a large operating cost base, with R&D of $7,577,704, sales and marketing of $4,443,807, and G&A of $6,646,037 in FY2025, resulting in an operating loss of $17,588,669.
Customers & Markets
Hospitals and healthcare practitioners in the women's reproductive health market. End market is female permanent contraception and gynecological device procedures.
Geographic Exposure
CE mark certification under EU MDR obtained in March 2025, indicating regulatory presence in the European Union. U.S. operations ongoing. No further geographic revenue breakdown supported by the filing excerpts.
Financial Snapshot
Loading...
